Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
rosiglitazone 6 endocrinologydiseasesdrugs
type 2 diabetes mellitus 1 endocrinologydiseases
glyburide 8 endocrinologydiseasesdrugs
pioglitazone 6 endocrinologydiseasesdrugs
metformin 7 endocrinologydiseasesdrugs
obesity 1 endocrinologydiseases
sitagliptin 3 endocrinologydiseasesdrugs
diabetes mellitus 2 endocrinologydiseases
hypoglycemia 2 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
glyburide 1439 comparing the impact on LVM between OADs, only gliclazide significantly reduced LVM compared to other OADs ( glyburide , voglibose, metformin, pioglitazone, rosiglitazone, and sitagliptin).ConclusionsIn the present study,
glyburide 9057 was 8.4 years, and average trial period was 32.3 weeks. Seven types of oral diabetes medication ( glyburide , gliclazide, voglibose, metformin, pioglitazone, rosiglitazone, and sitagliptin) and a placebo were
glyburide 10707 2000Diet + exercise24107 (g)8Giles et al. [[31]]2008US518633329.7NR11.68.9NRNR100Pioglitazone vs. glyburide Pioglitazone, 30; glyburide, 10Metformin and/or sulfonylurea24NR9Lee et al. [[14]].2007Taiwan108634426.6NR118.374NR0Glyburide
glyburide 10734 (g)8Giles et al. [[31]]2008US518633329.7NR11.68.9NRNR100Pioglitazone vs. glyburidePioglitazone, 30; glyburide , 10Metformin and/or sulfonylurea24NR9Lee et al. [[14]].2007Taiwan108634426.6NR118.374NR0Glyburide vs.
glyburide 13216 between OADs, the only significant difference that was identified was in the comparative trials between glyburide and gliclazide (SMD, −0.95; 95% CI, −1.29 to − 0.61), where the gliclazide cohort showed
glyburide 13372 to − 0.61), where the gliclazide cohort showed a significant decrease in LVM compared to the glyburide cohort.Table 3Results of network meta-analysis (data under the cells marked with italic drugs) and
glyburide 15844 RAnking curveInconsistency between direct and indirect evidenceOnly one closed loop (triangular loop: glyburide –pioglitazone–rosiglitazone) was found regarding local inconsistencies. There was no significant
glyburide 18581 minimal [[42]]. This is believed to be the reason why gliclazide significantly lowers LVM compared to glyburide , despite both being sulfonylureas.However, except gliclazide, no OADs exhibited significant LVM-lowering
metformin 1461 between OADs, only gliclazide significantly reduced LVM compared to other OADs (glyburide, voglibose, metformin , pioglitazone, rosiglitazone, and sitagliptin).ConclusionsIn the present study, gliclazide was the only
metformin 9091 period was 32.3 weeks. Seven types of oral diabetes medication (glyburide, gliclazide, voglibose, metformin , pioglitazone, rosiglitazone, and sitagliptin) and a placebo were included in the analysis.Fig. 1Study
metformin 9717 [[17]]2017Japan115693524.8NRNR6.976700Sitagliptin vs. conventionalSitagliptin, 25 or 50; conventional, α-glucosidase inhibitor/glinide/ metformin /sulfonylurea/pioglitazoneDiet + exercise9696.2 (g/m2)2Oe et al. [[18]]2015Japan77663525.7NR3NR80105Sitagliptin
metformin 10146 al. [[28]]2010Greece816472NR74.297.9NRNR0Pioglitazone vs. conventionalPioglitazone, 30; conventional, metformin /sulfonylureaMetformin and/or sulfonylurea24118.1 (g/m2)5McGuire et al. [[29]]2010US108553834978.77.2747537Rosiglitazone
metformin 10567 sulfonylurea16136 (g/m2)7van der Meer et al. [[19]]2009Netherlands7156NR29.3NRNR7NRNR0Pioglitazone vs. metformin Pioglitazone, 30; metformin, 2000Diet + exercise24107 (g)8Giles et al. [[31]]2008US518633329.7NR11.68.9NRNR100Pioglitazone
metformin 10594 der Meer et al. [[19]]2009Netherlands7156NR29.3NRNR7NRNR0Pioglitazone vs. metforminPioglitazone, 30; metformin , 2000Diet + exercise24107 (g)8Giles et al. [[31]]2008US518633329.7NR11.68.9NRNR100Pioglitazone vs.
metformin 19217 administration of incretin preparations has anti-inflammatory and LVM-lowering actions [[44], [45]]. While metformin is believed to exhibit anti-inflammatory and anti-oxidative actions, it has been reported that no LVM-lowering
pioglitazone 1472 only gliclazide significantly reduced LVM compared to other OADs (glyburide, voglibose, metformin, pioglitazone , rosiglitazone, and sitagliptin).ConclusionsIn the present study, gliclazide was the only medication
pioglitazone 9102 32.3 weeks. Seven types of oral diabetes medication (glyburide, gliclazide, voglibose, metformin, pioglitazone , rosiglitazone, and sitagliptin) and a placebo were included in the analysis.Fig. 1Study flow diagram.
pioglitazone 9740 conventionalSitagliptin, 25 or 50; conventional, α-glucosidase inhibitor/glinide/metformin/sulfonylurea/ pioglitazone Diet + exercise9696.2 (g/m2)2Oe et al. [[18]]2015Japan77663525.7NR3NR80105Sitagliptin vs. vogliboseSitagliptin,50;
pioglitazone 10401 8Diet + exercise2476 (g/m2)6Pala et al. [[30]]2010Turkey40556033NR4.48.465600Rosiglitazone vs. pioglitazone Rosiglitazone, 8; pioglitazone, 30Metformin and/or sulfonylurea16136 (g/m2)7van der Meer et al. [[19]]2009Netherlands7156NR29.3NRNR7NRNR0Pioglitazone
pioglitazone 10431 (g/m2)6Pala et al. [[30]]2010Turkey40556033NR4.48.465600Rosiglitazone vs. pioglitazoneRosiglitazone, 8; pioglitazone , 30Metformin and/or sulfonylurea16136 (g/m2)7van der Meer et al. [[19]]2009Netherlands7156NR29.3NRNR7NRNR0Pioglitazone
pioglitazone 15856 curveInconsistency between direct and indirect evidenceOnly one closed loop (triangular loop: glyburide– pioglitazone –rosiglitazone) was found regarding local inconsistencies. There was no significant difference in the
rosiglitazone 1486 gliclazide significantly reduced LVM compared to other OADs (glyburide, voglibose, metformin, pioglitazone, rosiglitazone , and sitagliptin).ConclusionsIn the present study, gliclazide was the only medication that significantly
rosiglitazone 9116 Seven types of oral diabetes medication (glyburide, gliclazide, voglibose, metformin, pioglitazone, rosiglitazone , and sitagliptin) and a placebo were included in the analysis.Fig. 1Study flow diagram. LVM left ventricular
rosiglitazone 11112 gliclazide, 80Glibenclamide24120 (g/m2)11Sutton et al. [[33]]2002US2035525NR86.25.39.1NRNR0Glyburide vs. rosiglitazone Glyburide, 10; rosiglitazone, 8Diet + exercise5275.5 (g/m2)Unless indicated otherwise, data are shown
rosiglitazone 11140 (g/m2)11Sutton et al. [[33]]2002US2035525NR86.25.39.1NRNR0Glyburide vs. rosiglitazoneGlyburide, 10; rosiglitazone , 8Diet + exercise5275.5 (g/m2)Unless indicated otherwise, data are shown as mean valuesDM diabetes
rosiglitazone 12969 the direct pairwise meta-analysis. One RCT compared OADs and a placebo in terms of the effect on LVM ( rosiglitazone vs. placebo), finding no statistically significant difference. Alternatively, among the studies that
rosiglitazone 15871 between direct and indirect evidenceOnly one closed loop (triangular loop: glyburide–pioglitazone– rosiglitazone ) was found regarding local inconsistencies. There was no significant difference in the loop-specific
sitagliptin 1505 reduced LVM compared to other OADs (glyburide, voglibose, metformin, pioglitazone, rosiglitazone, and sitagliptin ).ConclusionsIn the present study, gliclazide was the only medication that significantly reduced LVM
sitagliptin 9135 diabetes medication (glyburide, gliclazide, voglibose, metformin, pioglitazone, rosiglitazone, and sitagliptin ) and a placebo were included in the analysis.Fig. 1Study flow diagram. LVM left ventricular massTable 1Characteristics
sitagliptin 15415 results of the SUCRA analysis. The drug with the highest SUCRA values was gliclazide (99.6%), followed by sitagliptin (68.8%). The placebo has the lowest SUCRA values (28.1%).Table 4The rank of oral antidiabetic drugs
Select Disease Character Offset Disease Term Instance
diabetes mellitus 117 Cardiovascular DiabetologyEffects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus : a network meta-analysisSatoshi IdaRyutaro KanekoKazuya MurataPublication date (epub): 9/2018Publication
diabetes mellitus 11248 rosiglitazone, 8Diet + exercise5275.5 (g/m2)Unless indicated otherwise, data are shown as mean valuesDM diabetes mellitus , BMI body mass index, OADs oral antidiabetic drugs, LVM left ventricular mass, NR not reportedFig. 2Network
hypoglycemia 20924 need to be taken into consideration. While gliclazide is believed to have a relatively low risk of hypoglycemia among sulfonylureas, attention should be paid to the risk of hypoglycemia.LimitationsOur study has several
hypoglycemia 20998 a relatively low risk of hypoglycemia among sulfonylureas, attention should be paid to the risk of hypoglycemia .LimitationsOur study has several limitations. First, comparatively, few RCTs are included in this study,
obesity 16428 is believed that the mechanism of increased LVM is related to microvascular disease, inflammation, obesity , elevated oxidative stress, increased insulin resistance, myocardial fibrosis, left ventricular remodeling,
type 2 diabetes mellitus 110 Cardiovascular DiabetologyEffects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus : a network meta-analysisSatoshi IdaRyutaro KanekoKazuya MurataPublication date (epub): 9/2018Publication

You must be authorized to submit a review.